Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT04592653 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

ARTISTRY-3
Start date: September 30, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

NCT ID: NCT04349267 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Start date: July 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

NCT ID: NCT04328740 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Phase 1 Study of Oral TP-1454

Start date: July 8, 2020
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.

NCT ID: NCT04322006 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Start date: May 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to confirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safety, effectiveness, Pharmacokinetics, pharmacodynamics and biomarker properties for effective subjects.

NCT ID: NCT04259450 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study to Assess AFM24 in Advanced Solid Cancers

Start date: April 7, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody construct being developed to target EGFR-expressing solid tumors and has been designed to specifically utilize the cytotoxic potential of the innate immune system, in particular natural killer cells and macrophages for the specific and efficient elimination of EGFR-positive cancer cells.

NCT ID: NCT04242199 Active, not recruiting - Clinical trials for HepatoCellular Carcinoma

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Start date: September 4, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

NCT ID: NCT04215978 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Start date: January 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.

NCT ID: NCT04083976 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

RAGNAR
Start date: November 20, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric participants with advanced solid tumors and FGFR alterations.

NCT ID: NCT03993873 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

SHIELD-1
Start date: September 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

NCT ID: NCT03950570 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Start date: May 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in the advanced setting).